In sum, ITPRIPL1 has the potential as a proteomic immunohistochemical cancer biomarker for future clinical concerns, the positive rate of which can suggest the level of CD8 positive T cell infiltration and clinical outcome prognosis. The gene discussed is CD8A; the disease is cancer.